Open innovation and increased collaboration

Shaking hands

​The best brains can be found across different sectors and increased collaboration between industry, academia, the NHS and regulators must be fostered in order to achieve a reduction in the time it takes to develop new medicines for patients. 

This could take place in pre-competitive or non-competitive research, for example in areas such as predictive toxicology, drug target identification and validation and the identification of novel biomarkers. Some good examples are:

  • The Stem Cells for Safer Medicines public-private partnership, which specialises in the identification of stem cell derived cell lines for predictive toxicology –
  • The Innovative Medicines Initiative –
  • The MRC-ABPI immunology and inflammation initiative –
  • The Therapeutic Capability Clusters as proposed in the Office of Life Sciences 2009 Life Sciences Blueprint
Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.